Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

12:18
06/23/18
06/23
12:18
06/23/18
12:18

Eli Lilly's Trulicity shows promise in delivering efficacy in type 2 diabetes

Two investigational doses of Lilly's dulaglutide - 4.5 mg and 3.0 mg -, as well as Trulicity 1.5 mg, provided significantly better blood sugar control with weight benefits compared to placebo in adults with type 2 diabetes. Trulicity is Eli Lilly's once-weekly, injectable glucagon-like peptide-1 receptor agonist approved to improve blood sugar in adults with type 2 diabetes. At the study's primary endpoint of 18 weeks, the investigational dulaglutide 4.5 mg and 3.0 mg doses, as well as the currently approved Trulicity 1.5 mg dose, led to superior A1C reductions from baseline in people with type 2 diabetes who remained on treatment throughout the study compared to placebo. The investigational dulaglutide doses also led to significant weight loss compared to placebo, as did Trulicity 1.5 mg. The most commonly reported side effects were gastrointestinal-related and consistent with the GLP-1 RA class. These events included nausea. Trulicity 1.5 mg had a similar side effect profile to previous studies. No participants in any of the treatment groups experienced severe hypoglycemia. The safety and efficacy of the dulaglutide investigational doses are being studied further in a large, Phase 3 clinical trial, AWARD-11. The study is expected to complete in 2019.

  • 10

    Sep

LLY Eli Lilly
$85.90

-0.17 (-0.20%)

06/11/18
WELS
06/11/18
NO CHANGE
Target $240
WELS
Outperform
Allergan migraine data on lower end of relative efficiency, says Wells Fargo
Wells Fargo analyst David Maris says his initial review suggests Allergan's (AGN) atogepant's Phase IIb data are "relatively in-line but on the lower end of the efficacy" demonstrated by the calcitonin gene-related peptide migraine treatments in Phase III trials. Atogepant is expected to face competition from Amgen (AMGN)/Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), which are all developing injectable anti-CGRP treatments, as well as Alder Biopharmaceuticals (ALDR), which has an infusion-administered anti-CGRP in development, Maris tells investors in a research note. He notes that while Allergan will be following these competitors to the market, atogepant will be differentiated in that it is the only oral prophylactic anti-CGRP therapy. The analyst forecasts $75M in sales for atogepant in 2022. He does not believe many investors are giving Allergan credit for atogepant, meaning the "risk to the downside looks limited." Maris keeps an Outperform rating on Allergan shares.
06/13/18
JEFF
06/13/18
DOWNGRADE
Target $50
JEFF
Hold
Armo BioSciences downgraded to Hold from Buy at Jefferies
Jefferies analyst Biren Amin downgraded Armo BioSciences (ARMO) to Hold and lowered his price target for the shares to $50 from $61. The analyst expects the takeover by Eli Lilly (LLY) to close in a few weeks and does not expect a competing bid to emerge.
06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/15/18
PIPR
06/15/18
NO CHANGE
Target $85
PIPR
Overweight
Piper Jaffray sees better than expected U.S. launch for Olumiant
Piper Jaffray analyst Tyler Van Buren says he left a meeting with CEO of Eli Lilly (LLY) David Ricks with increased conviction in the U.S. launch of Olumiant. The analyst believes the launch will be better than investors currently anticipate and reiterates an Overweight rating on shares of Incyte (INCY) with an $85 price target. Van Buren expect payors to be "very receptive" to Olumiant pricing.

TODAY'S FREE FLY STORIES

I

Intelsat

$36.25

3.81 (11.74%)

14:25
10/16/18
10/16
14:25
10/16/18
14:25
Options
Intelsat call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
10/16/18
10/16
14:25
10/16/18
14:25
Conference/Events
Financial Stability Oversight Council to hold a meeting »

The Council will provide…

WBA

Walgreens Boots Alliance

$75.55

0.83 (1.11%)

, AMZN

Amazon.com

$1,811.22

50.23 (2.85%)

14:23
10/16/18
10/16
14:23
10/16/18
14:23
Periodicals
Walgreens CEO says buyout of AmerisourceBergen possible, Bloomberg reports »

Walgreens Boots Alliance…

WBA

Walgreens Boots Alliance

$75.55

0.83 (1.11%)

AMZN

Amazon.com

$1,811.22

50.23 (2.85%)

CVS

CVS Health

$73.05

0.01 (0.01%)

AET

Aetna

$199.90

0.88 (0.44%)

ABC

AmerisourceBergen

$92.51

2.93 (3.27%)

RAD

Rite Aid

$1.05

-0.005 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 25

    Oct

  • 06

    Nov

RP

RealPage

$58.71

2.33 (4.13%)

14:22
10/16/18
10/16
14:22
10/16/18
14:22
Hot Stocks
RealPage pays $3M to settle FTC charges over tenant screening »

RealPage has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

MARA

Marathon Patent Group

$0.62

-0.0034 (-0.55%)

14:18
10/16/18
10/16
14:18
10/16/18
14:18
Hot Stocks
Breaking Hot Stocks news story on Marathon Patent Group »

Merrick D. Okamoto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/16/18
10/16
14:17
10/16/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/16/18
10/16
14:16
10/16/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$220.75

5.47 (2.54%)

14:07
10/16/18
10/16
14:07
10/16/18
14:07
Recommendations
Goldman Sachs analyst commentary  »

JMP Securities sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 26

    Oct

DLTR

Dollar Tree

$86.09

5.11 (6.31%)

, DG

Dollar General

$110.50

4.08 (3.83%)

14:07
10/16/18
10/16
14:07
10/16/18
14:07
Recommendations
Dollar Tree, Dollar General, Amazon.com analyst commentary  »

Reported Icahn stake in…

DLTR

Dollar Tree

$86.09

5.11 (6.31%)

DG

Dollar General

$110.50

4.08 (3.83%)

AMZN

Amazon.com

$1,808.50

47.51 (2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 25

    Oct

CAG

Conagra Brands

$36.10

0.2725 (0.76%)

, PF

Pinnacle Foods

$66.45

0.22 (0.33%)

14:04
10/16/18
10/16
14:04
10/16/18
14:04
Conference/Events
Pinnacle Foods to host special shareholder meeting »

Special Shareholder…

CAG

Conagra Brands

$36.10

0.2725 (0.76%)

PF

Pinnacle Foods

$66.45

0.22 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

CRON

Cronos Group

$11.66

-0.07 (-0.60%)

14:00
10/16/18
10/16
14:00
10/16/18
14:00
Options
Cronos short-term calls active as shares see up and down action »

Cronos short-term calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABC

AmerisourceBergen

$90.56

0.98 (1.09%)

, WBA

Walgreens Boots Alliance

$75.52

0.8 (1.07%)

13:50
10/16/18
10/16
13:50
10/16/18
13:50
Periodicals
Walgreens CEO 'doesn't rule out' deal with AmerisourceBergen, Bloomberg says »

Walgreens (WBA) CEO…

ABC

AmerisourceBergen

$90.56

0.98 (1.09%)

WBA

Walgreens Boots Alliance

$75.52

0.8 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

CJREF

Corus Entertainment

$0.00

(0.00%)

13:49
10/16/18
10/16
13:49
10/16/18
13:49
Upgrade
Corus Entertainment rating change  »

Corus Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVMT

Dell Technologies

$95.51

0.52 (0.55%)

13:46
10/16/18
10/16
13:46
10/16/18
13:46
Periodicals
Dell still thinks offer 'in best interest of DVMT shareholders,' Bloomberg says »

Dell Technologies is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
10/16/18
10/16
13:45
10/16/18
13:45
General news
U.S. corporate bond update: several financials are on tap »

U.S. corporate bond…

FDC

First Data

$23.61

0.56 (2.43%)

13:40
10/16/18
10/16
13:40
10/16/18
13:40
Options
8K First Data Jan 25 - 27 call spreads trade for 55c »

8K First Data Jan 25 - 27…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 29

    Oct

  • 03

    Mar

SNE

Sony

$57.24

0.99 (1.76%)

, BTC

Bitcoin

$0.00

(0.00%)

13:35
10/16/18
10/16
13:35
10/16/18
13:35
Hot Stocks
Sony developing rights management system for digital content using blockchain »

Sony Corporation, Sony…

SNE

Sony

$57.24

0.99 (1.76%)

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:35
10/16/18
10/16
13:35
10/16/18
13:35
General news
Treasury Option Action: 10-year positioning »

Treasury Option Action:…

TTWO

Take-Two

$131.41

3.43 (2.68%)

, ATVI

Activision Blizzard

$77.79

2.09 (2.76%)

13:31
10/16/18
10/16
13:31
10/16/18
13:31
Hot Stocks
Game On: Pachter says 'Red Dead Online' could be 25% as popular as 'GTA Online' »

Welcome to "Game…

TTWO

Take-Two

$131.41

3.43 (2.68%)

ATVI

Activision Blizzard

$77.79

2.09 (2.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

WHR

Whirlpool

$108.01

2.6 (2.47%)

13:26
10/16/18
10/16
13:26
10/16/18
13:26
Periodicals
AHAM reports U.S. shipments of major home appliances down 0.4% in September »

The Association of Home…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

SYMC

Symantec

$20.20

0.42 (2.12%)

13:25
10/16/18
10/16
13:25
10/16/18
13:25
Options
Symantec call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Dec

13:25
10/16/18
10/16
13:25
10/16/18
13:25
Conference/Events
Credit Suisse energy analysts to hold an analyst/industry conference call »

Energy Analysts, along…

SGRY

Surgery Partners

$14.56

0.34 (2.39%)

, UNH

UnitedHealth

$270.48

10.68 (4.11%)

13:21
10/16/18
10/16
13:21
10/16/18
13:21
Hot Stocks
Surgery Partners strength attributed to TheDeal.com discussion of M&A potential »

Shares of Surgery…

SGRY

Surgery Partners

$14.56

0.34 (2.39%)

UNH

UnitedHealth

$270.48

10.68 (4.11%)

HCA

HCA Healthcare

$134.76

1.9 (1.43%)

THC

Tenet

$26.32

0.69 (2.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 30

    Oct

  • 06

    Nov

IBM

IBM

$144.39

3.27 (2.32%)

, AMZN

Amazon.com

$1,799.99

39 (2.21%)

13:19
10/16/18
10/16
13:19
10/16/18
13:19
Earnings
Fly Intel: What to watch for in IBM's earnings report »

IBM (IBM) is scheduled to…

IBM

IBM

$144.39

3.27 (2.32%)

AMZN

Amazon.com

$1,799.99

39 (2.21%)

MSFT

Microsoft

$110.61

3.01 (2.80%)

ORCL

Oracle

$48.18

1.06 (2.25%)

GOOG

Alphabet

$1,117.65

25.65 (2.35%)

GOOGL

Alphabet Class A

$1,130.17

28.59 (2.60%)

GRPN

Groupon

$3.59

0.085 (2.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 13

    Nov

  • 28

    Nov

  • 03

    Mar

XENT

Intersect ENT

$28.91

-1 (-3.34%)

, REGN

Regeneron

$396.44

18.64 (4.93%)

13:18
10/16/18
10/16
13:18
10/16/18
13:18
Recommendations
Intersect ENT, Regeneron analyst commentary  »

Regeneron data won't…

XENT

Intersect ENT

$28.91

-1 (-3.34%)

REGN

Regeneron

$396.44

18.64 (4.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 28

    Oct

  • 06

    Nov

  • 27

    Nov

  • 28

    Apr

  • 13

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.